Challenging current paradigms

Neoadjuvant Short-term Intensive Intravesical Mitomycin C Regimen Compared with Weekly Schedule for Low-grade Recurrent Non–muscle-invasive Bladder Cancer: Preliminary Results of a Randomised Phase 2 Study

(2012) Renzo Colombo et al.   EUROPEAN UROLOGY

Intracutaneous and Intravesical Immunotherapy With Keyhole Limpet Hemocyanin Compared With Intravesical Mitomycin in Patients With Non–Muscle-Invasive Bladder Cancer: Results From a Prospective Randomized Phase III Trial

(2012) Rianne J.M. Lammers et al.   JOURNAL OF CLINICAL ONCOLOGY

Randomized Phase III Study Comparing Paclitaxel/Cisplatin/ Gemcitabine and Gemcitabine/Cisplatin in Patients With Locally Advanced or Metastatic Urothelial Cancer Without Prior Systemic Therapy: EORTC Intergroup Study 30987

(2012) Joaquim Bellmunt et al.   JOURNAL OF CLINICAL ONCOLOGY

Association Between Longer Therapy With Thiazolidinediones and Risk of Bladder Cancer: A Cohort Study

(2012) Ronac Mamtani et al.   JNCI-Journal of the National Cancer Institute

Long-Term Impact of Arsenic in Drinking Water on Bladder Cancer Health Care and Mortality Rates 20 Years After End of Exposure

(2012) Mario I. Fernández et al.   JOURNAL OF UROLOGY

Pazopanib in advanced and platinum-resistant urothelial cancer: an open-label, single group, phase 2 trial

(2012) Andrea Necchi et al.   LANCET ONCOLOGY

Radiotherapy with or without Chemotherapy in Muscle-Invasive Bladder Cancer

(2012) Nicholas D. James et al.   NEW ENGLAND JOURNAL OF MEDICINE

Genome Sequencing Identifies a Basis for Everolimus Sensitivity

(2012) G. Iyer et al.   SCIENCE

A New and Highly Prognostic System to Discern T1 Bladder Cancer Substage

(2011) Bas W.G. van Rhijn et al.   EUROPEAN UROLOGY

Electromotive instillation of mitomycin immediately before transurethral resection for patients with primary urothelial non-muscle invasive bladder cancer: a randomised controlled trial

(2011) Savino M Di Stasi et al.   LANCET ONCOLOGY